pharma · Prurigo Nodularis · Vitiligo
Incyte
Incyte is a pharma organization headquartered in Wilmington, USA. Primary therapeutic focus areas include Prurigo Nodularis, Vitiligo, Hidradenitis Suppurativa, Chronic Graft-Versus-Host Disease, chronic graft-versus-hos
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
- Employees
- 3,381
- Programs
- 53
- Drugs
- 61
- Patents
- 0
INCAGN 2385-203
Phase 2 · small molecule · In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
INCAGN 2385-203 for In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. is a Phase 2 program (small_molecule) at Incyte with 1 ClinicalTrials.gov record(s).
Internal code INCAGN 2385-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Incyte
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
- Status
- active
- Trials
- 1